RADNOSTIX INC

IDAHO FALLS, IDAHO, August 13, 2026 — Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) (“Radnostix” or the “Company”), a manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its financial results for the second quarter and six months ended June 30, 2026 and the filing of its Quarterly Report on Form […] The post Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results – Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition first appeared on Radnostix.

IDAHO FALLS, IDAHO, July 2nd, 2026 – Radnostix, Inc. (OTCQB: INIS) (“Radnostix” or the “Company”), a leader in radioisotope production and nuclear medicine solutions, today announced the successful closing of its acquisition of key assets from Lucerno Dynamics, LLC, including the LARA® System technology platform, ELLEXA® Explorer software and associated intellectual property. The product line […] The post Radnostix Expands Radiopharma Medical Device Portfolio With Lucerno Dynamics Assets first appeared on Radnostix.

IDAHO FALLS, IDAHO, May 15, 2026 – Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) (“Radnostix” or the “Company”), a manufacturer of radioisotope-focused products for medical, industrial, and research applications, today announced its financial results for the first quarter ended March 31, 2026 and the filing of its Quarterly Report on Form 10-Q with the […] The post Radnostix, Inc. Reports FY2026 Q1 Results – Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown first appeared on Radnostix.

IDAHO FALLS, IDAHO, March 31, 2026. Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) (“Radnostix” or the “Company”), a leading manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its fiscal year 2025 financial results and corporate updates. Fiscal 2025 Highlights Total revenue reached $13.07 million, the second-highest annual revenue in Company […] The post Radnostix, Inc. Reports FY2025 Results – Second-Highest Annual Revenue in Company History; Delivers Strong Growth in Calibration & Reference Products and Advances Key Product Launches in 2025 first appeared on Radnostix.

IDAHO FALLS, IDAHO, March 16th, 2026. Radnostix, Inc. (formerly International Isotopes, Inc., “RNX” or the “Company”), announced a mutual termination of an Asset Purchase Agreement (the “APA”) dated February 8, 2024 entered into between RNX and its wholly owned subsidiary International Isotopes Fluorine Products, Inc. (together with RNX, the “Seller”) and American Fuel Resources, LLC […] The post Mutual Termination of the Asset Purchase Agreement related to the Radnostix DUF6 Assets first appeared on Radnostix.

IDAHO FALLS, Idaho & LANE COVE, Australia – October 23, 2025. International Isotopes, Inc. (“INIS”), a leading U.S. provider of medical isotopes and nuclear medicine solutions, today announced an exclusive partnership agreement with Australia-based Globalsonics Research Pty Ltd (“Globalsonics”). Under the terms of the agreement, INIS will become the authorized distributor, installer, and service provider […] The post International Isotopes Announces Exclusive North American Distribution and Service Agreement with Globalsonics Research Pty Ltd. first appeared on Radnostix.

Idaho Falls, ID – October 22th, 2025 – International Isotopes Inc. (OTCQB: INIS) (“INIS” or the “Company”), a leading provider of radiopharmaceuticals, radioisotope products, and nuclear medicine solutions, has appointment of Dr. Duke W. Fu to its Board of Directors, effective October 10th, 2025. Dr. Fu, a Board Certified Nuclear Pharmacist with over 20 years […] The post International Isotopes Inc. Appoints Dr. Duke W. Fu to Board of Directors first appeared on Radnostix.

Idaho Falls, ID – October 21st, 2025 – International Isotopes, Inc. (OTCQB: INIS) (“INIS” or the “Company”), together with American Fuel Resources LLC (“AFR”), has submitted an application to the U.S. Nuclear Regulatory Commission (NRC) requesting consent to transfer INIS’s New Mexico license to AFR’s wholly owned subsidiary, Green Salt Products LLC. This filing represents […] The post International Isotopes and AFR Submit NRC Consent Request for New Mexico License Transfer first appeared on Radnostix.

IDAHO FALLS, IDAHO, August 13, 2025. International Isotopes Inc. (OTCQB: INIS) (the “Company” or “INIS”) is pleased to announce its financial results for the second quarter and six months ended June 30, 2025. Revenue from the sale of product for the second quarter of 2025 was $3,655,320, an increase of $486,087 or 15.3%, compared to the […] The post International Isotopes, Inc. Announces Financial Results for the Second Quarter of 2025 first appeared on Radnostix.